What is Vycor Medical Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vycor Medical's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.04.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vycor Medical couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Vycor Medical's Cash-to-Debt or its related term are showing as below:
VYCO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.13 Max: 6.93
Current: 0.04
During the past 13 years, Vycor Medical's highest Cash to Debt Ratio was 6.93. The lowest was 0.03. And the median was 0.13.
Vycor Medical Cash-to-Debt Historical Data
The historical data trend for Vycor Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Vycor Medical Cash-to-Debt Chart
|
Vycor Medical Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.10 |
0.05 |
0.11 |
0.04 |
0.05 |
|
Vycor Medical Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.05 |
0.06 |
0.06 |
0.05 |
0.04 |
Competitive Comparison of Vycor Medical's Cash-to-Debt
For the Medical Devices subindustry, Vycor Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vycor Medical's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vycor Medical's Cash-to-Debt falls into.
Vycor Medical Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Vycor Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Vycor Medical's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vycor Medical (Vycor Medical) Business Description
Traded in Other Exchanges
N/A
Address
951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487
Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.
Executives
| David Cantor |
director, officer: President |
1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000 |
| Adrian Liddell |
director, officer: Chairman |
ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP |
| Peter C Zachariou |
director, 10 percent owner, officer: Chief Executive Officer |
C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014 |
| Lowell Rush |
director |
C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394 |
| Oscar Bronsther |
director |
4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380 |
| Steven Girgenti |
director |
C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013 |
| Fountainhead Capital Management Ltd |
10 percent owner |
PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP |
Vycor Medical (Vycor Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VYCO has been successfully added to your